Does Two Make A Trend? 3SBio Joins U.S.-listed Chinese Firms Going Private
This article was originally published in PharmAsia News
On the heels of ShangPharma, 3SBio’s move highlights depressed valuation for Chinese companies. The large premium should seal the deal for the company with a growing pipeline and revenues, analysts say.